Frontlight ResearchEarly access
Taking people in NetherlandsPhase 3
Comparing two PET scans for finding kidney cancer in adults
Compares two PET scans for detecting clear cell kidney cancer in adults.
Key facts
- Who runs it
- Stichting Radboud universitair medisch centrum
- Where
- Nijmegen, NetherlandsSee the site
- Trial code
- Registry title
- ISEE-RCC study
- Status
- Recruiting
- Phase
- Phase 3
- People taking part
- 20 people, planned
- Started
- 23 Sept 2025
- Expected to end
- 1 Jan 2027
- Type of study
- Interventional
- Record updated
- 18 May 2026
Who can take part
AI summary
From the trial's eligibility criteria. Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.
The trial is looking for adults whose kidney cancer (clear cell type) is suspected to have spread, based on a recent CT scan. It compares two PET scans.
- Age
- 18 years or older
- Sex
- All sexes can join
- Disease stage
- Suspected metastatic clear cell kidney cancer (ccRCC) on a contrast-enhanced CT done at most 4 weeks before the PET scan. Biopsy proof is not required. The primary tumor may still be in place or not.
- Earlier treatment
- No tyrosine kinase inhibitors within 1 month before joining. No radioisotope given within 10 physical half-lives before joining.
Main reasons for not taking part
- Past CAIX-negative, PSMA-negative or non-clear cell kidney cancer
- Kidney function GFR of 45 mL/min/1.73m2 or lower
- A second active cancer (except basal-cell carcinoma)
- Possible pregnancy or breastfeeding
- Known allergy or antibodies (HACA) against girentuximab or DFO
The registry criteria, word for word
Show all 10 criteriaShow less
Who can take part
- ≥ 18 years
- Suspicion of metastatic ccRCC on conventional contrast-enhanced CT (performed max. 4 weeks prior to the PET scan). Diagnosis may or may not be proven by biopsy prior to inclusion in the study. Primary tumor may or may not be in place
Who cannot take part
- Administration of tyrosine kinase inhibitors within 1 month prior to inclusion
- Administration of a radioisotope within 10 physical half-lives prior to study enrollment
- Possibility of pregnancy (anamnestic, if ambiguity; a pregnancy test will be conducted prior to the PET/CT) or lactation
- History of a CAIX-negative, PSMA negative or non-clear cell RCC
- Second active malignancy (except basal-cell carcinoma)
- Known hypersensitivity or formation of human anti-chimeric antibodies (HACA) against girentuximab or DFO
- Renal insufficiency with GFR ≤ 45 mL/min/1.73m2
- No verbal and written command of Dutch language
Where in Netherlands
- Stichting Radboud Universitair Medisch CentrumNijmegen, NetherlandsTaking people
About the trial
What the trial wants to find out
This explorative study aims to investigate and compare (both visually and semi-quantitatively) the tumor detection rates of 68Ga-gozetotide (PSMA) PET and 89Zr-DFO-girentuximab PET in patients suspected of having primary, recurrent or metastatic ccRCC.
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Contact the study team: see the registry record
Print a page for my doctorData and sources
- Registry record
- Listed on the EU's official list of trials (CTIS).
- Official title
- Intrapatient comparison of 68Ga-gozetotide (PSMA) PET and 89Zr-girentuximab PET in clear cell renal cell carcinoma (ISEE-RCC)
- Plain-language title
- Comparing two PET scans for finding kidney cancer in adultsGenerated from the registry record. The registry title is the official one.
- AI summary
- From the trial's eligibility criteria. Read by machine on 9 November 2026.
- Record updated
- 18 May 2026